AZN Oct 2024 77.500 call
| Previous close | 3.9000 |
| Open | 3.8600 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 77.50 |
| Expiry date | 2024-10-18 |
| Day's range | 3.8500 - 3.9000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
ZacksAstraZeneca (AZN) Falls on Failure to Meet NSCLC Study OS Goal
AstraZeneca's (AZN) shares decline as it fails to achieve statistically significant overall survival data in a late-stage NSCLC study on Dato-DXd compared with docetaxel.
GlobeNewswireCellectis Reports Financial Results for First Quarter 2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 20241; cash runway projection into 20262 • Conference call and webcast scheduled for tomorrow, May 29, 2024 at 8:00AM ET / 2:00PM CET NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and g
ZacksHere's Why Astrazeneca (AZN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
